188 related articles for article (PubMed ID: 31594689)
1. Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study.
Netter A; Pauly V; Siles P; Pivano A; Vidal V; Agostini A
Reprod Biomed Online; 2019 Nov; 39(5):795-801. PubMed ID: 31594689
[TBL] [Abstract][Full Text] [Related]
2. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
3. Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study.
Czuczwar P; Wozniak S; Szkodziak P; Milart P; Wozniakowska E; Wrona W; Paszkowski T
Ultrasound Obstet Gynecol; 2015 Jun; 45(6):744-50. PubMed ID: 25251811
[TBL] [Abstract][Full Text] [Related]
4. Influence of Ulipristal Acetate Therapy on Uterine Fibroid-Related Symptoms and on Uterine and Fibroid Volumes and Vascularity Indices Assessed by Ultrasound.
Baggio S; Pomini P; Galeone F; Presti F; Santi L; Raffaelli R; Franchi M
J Ultrasound Med; 2018 Sep; 37(9):2215-2223. PubMed ID: 29498074
[TBL] [Abstract][Full Text] [Related]
5. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term intermittent pharmacological therapy with ulipristal acetate on reducing the volume of uterine fibroids and relieving symptoms.
Kyeong HK; Choi J; Na YJ; Kim HG
Minerva Obstet Gynecol; 2023 Jun; 75(3):236-242. PubMed ID: 36786781
[TBL] [Abstract][Full Text] [Related]
7. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
8. Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study.
Frijlingh M; De Milliano I; Hehenkamp WJK; Huirne JAF
Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():186-192. PubMed ID: 31679806
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
10. Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial.
Verguts J; Godin PA; De Vree B; Donnez O; Cosyns S; Luyckx M; Nisolle M
Int J Gynaecol Obstet; 2019 Dec; 147(3):339-343. PubMed ID: 31502668
[TBL] [Abstract][Full Text] [Related]
11. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Morgante G; Centini G; Troìa L; Orvieto R; De Leo V
Reprod Biol Endocrinol; 2020 May; 18(1):50. PubMed ID: 32430027
[TBL] [Abstract][Full Text] [Related]
12. Measurement of changes in uterine and fibroid volume during treatment of heavy menstrual bleeding (HMB).
Yin K; Whitaker L; Hojo E; McLenachan S; Walker J; McKillop G; Stubbs C; Priest L; Cruz M; Roberts N; Critchley H
Hum Reprod Open; 2023; 2023(3):hoad021. PubMed ID: 37304815
[TBL] [Abstract][Full Text] [Related]
13. Management of women with uterine fibroids in reproductive center: retrospective analysis of clinical and reproductive outcomes.
Miriello D; Galanti F; Meneghini C; Fabiani C; Dal Lago A; Schiavi MC; Rago R
Minerva Obstet Gynecol; 2022 Apr; 74(2):130-136. PubMed ID: 33876897
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.
Brun JL; Rajaonarison J; Froeliger A; Monseau-Thiburce AC; Randriamboavonjy R; Vogler A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():13-18. PubMed ID: 29328939
[TBL] [Abstract][Full Text] [Related]
15. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
16. Changes in sexuality during ulipristal acetate treatment in women with symptomatic uterine fibroids.
Tuschy B; Gabbert M; Weiss C; Hornemann A; Wuhrer A; Sütterlin M; Berlit S
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():106-110. PubMed ID: 29920429
[TBL] [Abstract][Full Text] [Related]
17. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
18. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
20. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]